184 related articles for article (PubMed ID: 8712919)
1. Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions.
Piirainen L; Airaksinen A; Hovi T; Roivainen M
Arch Virol; 1996; 141(6):1011-20. PubMed ID: 8712919
[TBL] [Abstract][Full Text] [Related]
2. Efficient RGD-independent entry process of coxsackievirus A9.
Roivainen M; Piirainen L; Hovi T
Arch Virol; 1996; 141(10):1909-19. PubMed ID: 8920824
[TBL] [Abstract][Full Text] [Related]
3. Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles.
Fricks CE; Icenogle JP; Hogle JM
J Virol; 1985 Jun; 54(3):856-9. PubMed ID: 2987536
[TBL] [Abstract][Full Text] [Related]
4. Recurrent isolation of poliovirus 3 strains with chimeric capsid protein Vp1 suggests a recombination hot-spot site in Vp1.
Blomqvist S; Savolainen-Kopra C; Paananen A; El Bassioni L; El Maamoon Nasr EM; Firstova L; Zamiatina N; Kutateladze T; Roivainen M
Virus Res; 2010 Aug; 151(2):246-51. PubMed ID: 20493912
[TBL] [Abstract][Full Text] [Related]
5. Two amino acid substitutions in the type 3 poliovirus capsid contribute to the establishment of persistent infection in HEp-2c cells by modifying virus-receptor interactions.
Duncan G; Pelletier I; Colbère-Garapin F
Virology; 1998 Feb; 241(1):14-29. PubMed ID: 9454713
[TBL] [Abstract][Full Text] [Related]
6. Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating.
Couderc T; Delpeyroux F; Le Blay H; Blondel B
J Virol; 1996 Jan; 70(1):305-12. PubMed ID: 8523541
[TBL] [Abstract][Full Text] [Related]
7. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
Burns CC; Shaw J; Campagnoli R; Jorba J; Vincent A; Quay J; Kew O
J Virol; 2006 Apr; 80(7):3259-72. PubMed ID: 16537593
[TBL] [Abstract][Full Text] [Related]
8. Isolation of escape mutants of a hybrid poliovirus with the aid of insert-specific polyclonal antibodies.
Hovi T; Huovilainen A; Murdin A; Wimmer E
J Gen Virol; 1995 Jul; 76 ( Pt 7)():1861-5. PubMed ID: 9049393
[TBL] [Abstract][Full Text] [Related]
9. Poliovirus infection without accumulation of eclipse particles.
Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
Antiviral Res; 1995 Jan; 26(1):27-35. PubMed ID: 7741519
[TBL] [Abstract][Full Text] [Related]
10. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
11. Interaction of poliovirus with its cell surface binding site.
Bibb JA; Witherell G; Bernhardt G; Wimmer E
Virology; 1994 May; 201(1):107-15. PubMed ID: 8178474
[TBL] [Abstract][Full Text] [Related]
12. A mutation in VP4 defines a new step in the late stages of cell entry by poliovirus.
Moscufo N; Yafal AG; Rogove A; Hogle J; Chow M
J Virol; 1993 Aug; 67(8):5075-8. PubMed ID: 8392631
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic analysis of revertants from a poliovirus mutant that is specifically adapted to the mouse spinal cord.
Jia Q; Hogle JM; Hashikawa T; Nomoto A
J Virol; 2001 Dec; 75(23):11766-72. PubMed ID: 11689657
[TBL] [Abstract][Full Text] [Related]
14. Mouse neurovirulence determinants of poliovirus type 1 strain LS-a map to the coding regions of capsid protein VP1 and proteinase 2Apro.
Lu HH; Yang CF; Murdin AD; Klein MH; Harber JJ; Kew OM; Wimmer E
J Virol; 1994 Nov; 68(11):7507-15. PubMed ID: 7933134
[TBL] [Abstract][Full Text] [Related]
15. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.
Roivainen M; Hovi T
J Virol; 1988 Sep; 62(9):3536-9. PubMed ID: 2841503
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component.
Piirainen L; Roivainen M; Litmanen L; Eskola J; Beuvery EC; Hovi T
Vaccine; 1997 Feb; 15(2):237-43. PubMed ID: 9066044
[TBL] [Abstract][Full Text] [Related]
17. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
18. Use of a Glycan Library Reveals a New Model for Enteric Virus Oligosaccharide Binding and Virion Stabilization.
Lu H; Lehrman MA; Pfeiffer JK
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852778
[TBL] [Abstract][Full Text] [Related]
19. A Single Amino Acid Substitution in Poliovirus Nonstructural Protein 2CATPase Causes Conditional Defects in Encapsidation and Uncoating.
Asare E; Mugavero J; Jiang P; Wimmer E; Paul AV
J Virol; 2016 Jul; 90(14):6174-6186. PubMed ID: 27076638
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA.
Ansardi DC; Luo M; Morrow CD
Virology; 1994 Feb; 199(1):20-34. PubMed ID: 8116243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
